Afatinib Osimertinib Sequencing NIS

Boehringer Ingelheim204 enrolled

Overview

This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line treatment followed by osimertinib in case the T790M resistance mutation was developed.

Study Type

OBSERVATIONAL

Enrollment

204

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

AfatinibDRUG

GILOTRIF, GIOTRIF, XOVOLTIB

OsimertinibDRUG

on T790M resistance mutation was developed

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) * The tumour harbours common EGFR mutations (Del19, L858R) at start of first-line treatment * Patients who initiated second-line osimertinib treatment for acquired T790M mutation at least 10 months prior to data entry, AND who were treated with afatinib (Gi(l)otrif®) in the first-line * Patients treated with osimertinib within an EAP/CUP or regular clinical practice * Age ≥ 18 years * Signed and dated written informed consent per regulations (Exemption of a written informed consent for NIS based on existing data in countries per local regulations and legal requirements) Exclusion Criteria: * Patients who received drug(s) other than osimertinib as the second-line treatment and/or patients who received drug(s) other than afatinib (Gi(l)otrif®) as the first-line treatment * Patients with active brain metastases at start of treatment (either afatinib/Gi(l)otrif® or osimertinib)

Locations (1)

Otto-Wagner Hospital

Vienna, Austria

Outcomes

Primary Outcomes

Time on Treatment With Afatinib (Gi(l)Otrif®) Followed by Osimertinib

Time on treatment, which was defined as time in months from the start date of Afatinib (Gi\[l\]otrif®) treatment ('start date of initial dose' for First-Line Treatment) to the end date of Osimertinib treatment (maximum between 'end date of initial dose' and the last 'end date of dose modification' for Second-Line Treatment) or death date due to any cause ('date of death'). Time on treatment (months) = Time on treatment (days)/30.4375. 'Time on treatment was analysed using Kaplan-Meier method, and the median along with two-sided 90% confidence interval was displayed using the Greenwood's formula for estimation of standard errors.

Time frame: Data collected from start of treatment until data entry completion, up to 96.8 months for first analysis and up to 114.1 months for the extension analysis.

Secondary Outcomes

The Percentage of Participants With Different Types of Mutations After Categorisation

Different types of resistance mutations identified at the time of discontinuation of osimertinib treatment were systematically reviewed and categorised.

Time frame: Data collected from start of treatment until data entry completion; up to 96.8 months.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.